FDA, Kaiser Discussing COX-2 Myocardial Infarction Study

FDA may use the Kaiser database to help assess the cardiovascular risk profile of COX-2 inhibitors

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet